Laboratory Developed Test Market to Grow at a CAGR of 7.0% to reach US$ 7,269.3 million from 2021 to 2028
Si prevede che il mercato dei test sviluppati in laboratorio raggiungerà i 7.269,3 milioni di dollari entro il 2028 rispetto ai 4.524,75 milioni di dollari del 2021; si prevede che crescerà a un CAGR del 7,0% nel periodo 2021-2028.
Un test sviluppato in laboratorio (LDT) è un tipo di test diagnostico in vitro progettato e utilizzato all'interno di un singolo laboratorio. Questi test possono essere utilizzati per stimare o distinguere analiti come proteine, biomolecole/composti (glucosio, colesterolo, ecc.) e DNA estratto da campioni raccolti da soggetti umani. L’espansione dei metodi di diagnostica in vitro automatizzata (IVD) per laboratori e dispensari per eseguire analisi precise e prive di errori sta alimentando la crescita del mercato dei test sviluppati in laboratorio.
La crescita del mercato dei test sviluppati in laboratorio è principalmente attribuita a fattori quali l’aumento dei casi di cancro e malattie genetiche e il gran numero di lanci di prodotti. Tuttavia, il cambiamento del panorama normativo sta ostacolando la crescita del mercato. Ad esempio, in Europa, la conformità al regolamento sui dispositivi in vitro (IVDR) sarà obbligatoria per tutti i test diagnostici in vitro a partire da maggio 2022; il regolamento mira a garantire l’efficacia clinica e la sicurezza dei test medici, trasformando così l’industria diagnostica, che rappresenta una grande preoccupazione per gli operatori del mercato.
Personalizza la ricerca in base alle tue esigenze
Possiamo ottimizzare e personalizzare l'analisi e l'ambito che non sono soddisfatti dalle nostre offerte standard. Questa flessibilità ti aiuterà a ottenere le informazioni esatte necessarie per la pianificazione aziendale e il processo decisionale.
Mercato dei test sviluppati in laboratorio: approfondimenti strategici
CAGR (2021 - 2028)7,0%- Dimensione del mercato nel 2021:
4,52 miliardi di dollari - Dimensione del mercato nel 2028:
7,27 miliardi di dollari
Dinamiche di mercato
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
Giocatori chiave
- Quest Diagnostics Incorporated
- F. HOFFMANN-LA ROCHE LTD.,
- QIAGEN
- Illumina, Inc.,
- Eurofins Scientifico
- Biodesix
- Biotecnologie adattive
- Bioteranostica
- Rosetta Genomics Ltd.,
Panoramica regionale
- Nord America
- Europa
- Asia-Pacifico
- America meridionale e centrale
- Medio Oriente e Africa
Segmentazione del mercato
- Biochimica clinica
- Terapia intensiva
- Ematologia
- Microbiologia
- Diagnostica molecolare
- Immunologia
- Altri
- Istituti accademici
- Organizzazioni di ricerca clinica
- Laboratorio degli ospedali
- Centri diagnostici specializzati
- Altri
- Il PDF di esempio mostra la struttura del contenuto e la natura delle informazioni con analisi qualitative e quantitative.
Approfondimenti di mercato
La ricerca continua sui farmaci personalizzati offre opportunità di crescita agli attori del mercato dei test sviluppati in laboratorio
Gli LDT svolgono un ruolo vitale nello sviluppo di farmaci personalizzati che probabilmente si riveleranno un mezzo promettente per affrontare le malattie attraverso trattamenti o cure efficaci finora sfuggiti. Secondo la Personalized Medicine Coalition, i farmaci personalizzati rappresentavano solo il 5% delle nuove entità molecolari approvate dalla FDA nel 2005; tuttavia, nel 2016, questo numero è salito a oltre il 25%. Inoltre, il 42% di tutti i composti e il 73% dei composti oncologici in cantiere hanno il potenziale per fungere da farmaci personalizzati. Le aziende biofarmaceutiche hanno quasi raddoppiato i loro investimenti in ricerca e sviluppo in farmaci personalizzati negli ultimi cinque anni e si prevede che aumenteranno ulteriormente i loro investimenti del 33% nei prossimi cinque anni. I ricercatori biofarmaceutici prevedono inoltre un aumento del 69% nello sviluppo di farmaci personalizzati nei prossimi cinque anni. I test di laboratorio vengono utilizzati per diagnosticare malattie e prevedere e monitorare la risposta ai farmaci, nonché per ottenere i dati informatici necessari per algoritmi predittivi complessi.
Le medicine personalizzate stanno diventando il marchio di fabbrica del trattamento del cancro; è un approccio in continua evoluzione che si basa sulla personalizzazione dei trattamenti in base al corredo genetico individuale. Nel 2019, la FDA ha approvato 12 farmaci personalizzati per indagare e affrontare le cause profonde delle malattie, combinando così la medicina di precisione con l’assistenza clinica. La crescente domanda di medicina personalizzata offre significative opportunità di crescita per gli attori che operano nel mercato dei test sviluppati in laboratorio.
Approfondimenti basati sul tipo
Il mercato dei test sviluppati in laboratorio, per tipologia, è segmentato in biochimica clinica, terapia intensiva, ematologia, microbiologia, diagnostica molecolare, immunologia e altri. Si prevede che il segmento della diagnostica molecolare deterrà la quota maggiore del mercato nel 2021. Tuttavia, si prevede che il segmento dell’ematologia registrerà il CAGR più elevato sul mercato durante il periodo di previsione.
Approfondimenti basati sulle applicazioni
Per applicazione, il laboratorio ha sviluppato applicazioni di mercato per test in istituti accademici, organizzazioni di ricerca clinica, laboratori ospedalieri, centri diagnostici specializzati e altri. Si stima che il segmento dei laboratori ospedalieri rappresenterà la quota di mercato maggiore nel 2021. Tuttavia, si prevede che il segmento dei centri diagnostici specialistici registrerà il CAGR più elevato sul mercato durante il periodo di previsione.
Il lancio e l’approvazione dei prodotti sono strategie comunemente adottate dalle aziende per espandere la propria presenza globale e i portafogli di prodotti. Inoltre, gli operatori del mercato di prova sviluppato in laboratorio si concentrano sulla strategia di partnership per ampliare la propria clientela, che, a sua volta, consente loro di mantenere il proprio marchio a livello globale.
Il rapporto segmenta il mercato dei test sviluppati in laboratorio come segue
In base alla tipologia, il mercato dei test sviluppati in laboratorio è segmentato in biochimica clinica, terapia intensiva, ematologia, microbiologia, diagnostica molecolare, immunologia e altri. In base all'applicazione, il mercato dei test sviluppati in laboratorio è segmentato in istituti accademici, organizzazioni di ricerca clinica, laboratori ospedalieri, centri diagnostici specializzati e altri. Sulla base della geografia, il mercato dei test sviluppati in laboratorio è segmentato in Nord America (Stati Uniti, Canada e Messico), Europa (Regno Unito, Germania, Francia, Italia, Spagna e resto d’Europa), Asia Pacifico (Cina, Giappone, India, Australia, Corea del Sud e resto dell'Asia Pacifico), Medio Oriente e Africa (EAU, Arabia Saudita, Sud Africa e resto del Medio Oriente e Africa) e America meridionale e centrale (Brasile, Argentina , e il resto dell'America meridionale e centrale).
Ambito del rapporto di mercato dei test sviluppati in laboratorio
Attributo del rapporto | Dettagli |
---|---|
Dimensioni del mercato nel 2021 | 4,52 miliardi di dollari |
Dimensioni del mercato entro il 2028 | 7,27 miliardi di dollari |
CAGR globale (2021-2028) | 7,0% |
Dati storici | 2019-2020 |
Periodo di previsione | 2022-2028 |
Segmenti coperti | Per tipo
|
Regioni e paesi coperti | Nord America
|
Leader di mercato e profili aziendali chiave |
|
- Il PDF di esempio mostra la struttura del contenuto e la natura delle informazioni con analisi qualitative e quantitative.
Profili aziendali
- Quest Diagnostics Incorporated
- F. HOFFMANN-LA ROCHE LTD.,
- QIAGEN
- Illumina, Inc.,
- Eurofins Scientifico
- Biodesix
- Biotecnologie adattive
- Bioteranostica
- Rosetta Genomics Ltd.,
- Guardante Salute
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The laboratory developed test market is led by type molecular diagnostics segment is growing significantly due to the increasing attention to the development of genetic therapeutics. The growing research in human genomics is playing a vital role in developing laboratory developed tests. The technological advantages of molecular tests make them compelling diagnostic tools, and they have become valuable for detecting a wide range of genetic diseases. For instance, in November 2017, Edico Genome launched the DRAGEN Clinical Genomics Information System (CGIS).
The automation of LDTs can significantly boost productivity and simplify compliance procedures. Clinical laboratories are under huge pressure to manage increasing test volumes and conduct more complex diagnostic assays, which further underlines the need for flexible automation systems. Many MedTech companies are offering automation solutions to help streamline clinical laboratory processes. For instance, Roche Cobas Omni–Utility Channel is beneficial for both IVD assays and high-volume LDTs. It is designed to meet the growing needs of efficient workflows in laboratories, as it can assist in different stages ranging from sample processing to quick data interpretation. It can run up to 96 results in about 3 hours and up to 864 results in 8 hours, thereby boosting the efficiency of laboratories.
The growth of the region is attributed to factors such as rising public–private partnerships, and increasing funding activities are widely enhancing the performance of medical devices. Moreover, presence of well-developed healthcare infrastructure and government support are some of the prominent factors propelling the market growth in Asia Pacific. In Asia Pacific, India is the largest market for laboratory developed test. The market growth in Asia Pacific is mainly attributed to factors such as the growing usage of laboratory developed test in combating Covid-19, increasing incidents of cancer and genetic disorders, large number of product launches. However concerns high capital investment for setting up advanced labs hinders the market growth in Asia Pacific.
A laboratory developed test (LDT) is a type of in vitro diagnostic test that is designed and used within a single laboratory. These tests can be utilized to estimate or distinguish an extensive assortment of analytes materials such as proteins, chemical compounds like glucose or cholesterol, or DNA, from a specimen received from human anatomy. The expansion of automated in vitro diagnostics (IVD) methods for labs and dispensaries to render precise, and error-free analysis is anticipated to fuel the increment.
The growth of the laboratory developed test market is mainly attributed to factors such as the increasing incidents of cancer and genetic disorders, large number of product launches. However, changing regulatory landscape for instance, in Europe, the In-Vitro Device Regulation (IVDR) compliance will be mandatory for all in vitro diagnostic tests from May 2022; the regulation aims to secure the clinical effectiveness and safety of medical tests, thus transforming the diagnostic industry is a great concern to hinder the market growth. In August 2021, eMed, a telehealth company democratizing healthcare through digital-point-of-care solutions, and Quest Diagnostics the world's leading provider of diagnostic information services, are collaborated to bring clinician-guided rapid antigen testing for COVID-19 to employers seeking to foster safer environments by decreasing the risk of COVID-19 exposure in their workplaces which is contributing to the growth of the target market. Such strategic steps are also projected to drive the market growth.
The List of Companies - Laboratory Developed Test Market
- Quest Diagnostics Incorporated
- F. HOFFMANN-LA ROCHE LTD.,
- QIAGEN
- Illumina, Inc.,
- Eurofins Scientific
- Biodesix
- Adaptive Biotechnologies
- Biotheranostics
- Rosetta Genomics Ltd.,
- Guardant Health
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.